Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WCK 2349 Thorough QT Study in Healthy Volunteers
NCT02217930Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Aug 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of alalevonadifloxacin in bacterial infection (3 arms), sponsored by Wockhardt. Primary endpoint: Change in QTc interval at 48 hours. Started Aug 2014; status: completed.
02
Drugs
alalevonadifloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT02217930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217930.